about
Molecular markers of early Parkinson's disease based on gene expression in bloodUse of ibuprofen and risk of Parkinson diseaseConsumption of dairy products and risk of Parkinson's diseaseNonsteroidal antiinflammatory drug use and the risk for Parkinson's diseaseNonsteroidal anti-inflammatory drugs and the risk of Parkinson diseaseRole of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complicationsThe sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemiaMeeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohortNeuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and releaseInteractions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian miceThe epidemiology of Parkinson's disease: risk factors and prevention.Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells.Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses.Restless legs syndrome and erectile dysfunction.Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degenerationSerum cholesterol and the progression of Parkinson's disease: results from DATATOP.Urate as a predictor of the rate of clinical decline in Parkinson disease.Calcium channel blocker use and risk of Parkinson's disease.Prenatal and early life factors and risk of Parkinson's disease.Plasma urate and Parkinson's disease in women.Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection.Particulate matter and risk of Parkinson disease in a large prospective study of women.Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's diseasePesticide exposure and risk for Parkinson's disease.Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine.Targeting adenosine A2A receptors in Parkinson's disease.Mendelian randomization of serum urate and parkinson disease progression.Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality.Pathophysiological roles for purines: adenosine, caffeine and urate.Restless legs syndrome and Parkinson's disease in men.DARPP chocolate: a caffeinated morsel of striatal signaling.
P50
Q24292810-7F2C9F8D-9637-49B4-A357-6077C7D42EE0Q24594751-5217FDBC-DA9C-4BE1-B322-B8E8D28665C5Q24653226-18E115A4-7795-474A-BB1F-4590B09BB97BQ28192834-D5AB8839-1BFD-4AB1-8222-F7AB52F085CFQ28199468-B02B5C30-A8BA-486F-A069-B5000E20281AQ28247343-F3ED269F-5713-4E03-BC45-BB8D7034DEAFQ28255782-E6B09E4C-EA95-4814-85D0-020796E42103Q28387116-A49DA5FE-293B-4F53-912A-86C5C8E9FBCBQ28393626-085749F9-4181-48FB-84F8-36458C253D1EQ28393646-0B70B28C-E8E7-48EF-941B-EB24B4114A62Q28589507-FBA156C2-1298-44D5-BD82-D4C1430E6604Q30244421-22180EF5-4914-4310-964F-AFB294D2D414Q30311230-3BCB933B-602E-46B2-850F-2768D78D74EBQ30440692-61D02307-6EF7-47B4-BF9E-A9D5FAEEC31EQ33200599-D6E99520-03FF-48D3-8C2C-94ECAA4CF2CFQ33573869-B77FDBF9-84DB-46B5-9652-8151B1E13DDAQ33602588-D5AB6A37-AD3A-401C-BD3B-406C4FE7B3EEQ33645872-C691669D-990F-4DF7-9E04-AC6DE80277F3Q33828847-E5ADC501-7352-4493-AA3A-30AE75D39C9AQ33996828-B2B7478F-4EF0-4376-9824-90D20BB343DFQ34019732-CC255B2D-6539-43CB-AA3A-07243998067CQ34126927-6802D178-E115-46C1-A357-8FC60DE7D853Q34133288-E941D96E-F5F9-4832-9BAD-F96968377433Q34179611-2D7A9E3A-3ABD-4751-A7F2-6C64D73A8568Q34269340-C0B27A6F-4CB9-4CFE-9E8F-D3B73BAAD704Q34273978-CD95BFBE-1B41-4E51-A914-061EAC97F192Q34295209-7000F396-A2CD-4032-89B7-D74A799BE500Q34363409-D20ECD7C-824B-43B4-BB10-15E12CFD2F93Q34419833-2D208375-CDB1-41BB-B1C6-B1BC6AB96D5FQ34542115-6D087CAE-D0D7-4D54-A4A6-9884213F8C71Q34558649-599A6A76-42BE-4419-9742-D30122E6D5CFQ34571644-FCD2F94D-8689-46D3-BC96-D09E5FF16054Q34576895-A099E225-2BDB-4036-9182-C2E914DD8A4EQ34611348-4C84A85B-0B6E-44E3-9325-1E043E6F6145Q34629589-83A3337A-619C-4D3F-81F4-01D41DF80374Q34658560-51B479EA-B0DA-4CAD-98A7-79F7E40E1E7BQ34917908-40A4C26B-95CC-4E1B-B471-66F1CA181BA8Q35008049-6F526882-6EE2-4379-AD1A-A4386BB9A1ADQ35044966-8009FF68-4980-443B-B7D8-8E73314DCF4EQ35044987-BAE5561D-0AEC-42BB-BAF5-3EE495CB508C
P50
name
Michael A Schwarzschild
@ast
Michael A Schwarzschild
@en
Michael A Schwarzschild
@es
Michael A Schwarzschild
@nl
type
label
Michael A Schwarzschild
@ast
Michael A Schwarzschild
@en
Michael A Schwarzschild
@es
Michael A Schwarzschild
@nl
prefLabel
Michael A Schwarzschild
@ast
Michael A Schwarzschild
@en
Michael A Schwarzschild
@es
Michael A Schwarzschild
@nl
P214
P214
P31
P734
P735
P7859
viaf-171325644